APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon-like Peptide-2 (GLP-2) Agonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchGlucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glucagon-like Peptide-2 (GLP-2) Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Glucagon-like Peptide-2 (GLP-2) Agonist market include Takeda Pharmaceuticals. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Glucagon-like Peptide-2 (GLP-2) Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glucagon-like Peptide-2 (GLP-2) Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glucagon-like Peptide-2 (GLP-2) Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glucagon-like Peptide-2 (GLP-2) Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Company

Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type

Gattex

Revestive

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application

Hospital

Pharmacy

Other

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Glucagon-like Peptide-2 (GLP-2) Agonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Glucagon-like Peptide-2 (GLP-2) Agonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glucagon-like Peptide-2 (GLP-2) Agonist significant trends, drivers, influence factors in global and regions.

6. To analyze Glucagon-like Peptide-2 (GLP-2) Agonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon-like Peptide-2 (GLP-2) Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon-like Peptide-2 (GLP-2) Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glucagon-like Peptide-2 (GLP-2) Agonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glucagon-like Peptide-2 (GLP-2) Agonist industry.

Chapter 3: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Glucagon-like Peptide-2 (GLP-2) Agonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends Table 2. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers Table 3. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges Table 4. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Company (2021-2026) Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Company (2021-2026) Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Company Manufacturing Base & Headquarters Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company, Product Type & Application Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Gattex Table 18. Significant Companies of Revestive Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Type (2021-2026) Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Type (2027-2032) Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type (2021-2026) Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Application (2021-2026) Table 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Application (2027-2032) Table 37. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application (2021-2026) Table 41. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application (2027-2032) Table 42. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (K Units) Table 44. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2026) Table 45. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032) & (K Units) Table 46. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2027-2032) Table 47. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Region (2021-2026) Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Region (2027-2032) Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2026) Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2027-2032) Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Market Share by Country (2021-2026) Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Market Share by Country (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List Table 72. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Product Image Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032) & (K Units) Figure 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Gattex Image Figure 10. Revestive Image Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Type (2021-2032) Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Application (2021-2032) Figure 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application (2021-2032) Figure 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 31. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 37. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Gattex
  • Revestive
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  4. 1.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume (2021-2032)
  5. 1.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Dynamics
  1. 2.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
  2. 2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers
  3. 2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges
  4. 2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints
3 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Company
  1. 3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Revenue Ranking in 2025
  2. 3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2021-2026)
  3. 3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Company (2021-2026)
  4. 3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Company (2021-2026)
  5. 3.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Ranking (2024-2026)
  6. 3.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Manufacturing Base and Headquarters
  7. 3.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Product Type and Application
  8. 3.8 Global Glucagon-like Peptide-2 (GLP-2) Agonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Glucagon-like Peptide-2 (GLP-2) Agonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Type
  1. 4.1 Glucagon-like Peptide-2 (GLP-2) Agonist Type Introduction
  2. 4.1.1 Gattex
  3. 4.1.2 Revestive
  4. 4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type
  5. 4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type
  9. 4.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Type (2021-2032)
  11. 4.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type (2021-2032)
5 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Application
  1. 5.1 Glucagon-like Peptide-2 (GLP-2) Agonist Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application
  6. 5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application
  10. 5.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application (2021-2032)
6 Glucagon-like Peptide-2 (GLP-2) Agonist Regional Sales and Value Analysis
  1. 6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021-2026
  4. 6.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032)
  5. 6.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Region (2027-2032)
  9. 6.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  12. 6.6.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  15. 6.7.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  21. 6.9.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Country, 2025 VS 2032
7 Glucagon-like Peptide-2 (GLP-2) Agonist Country-level Sales and Value Analysis
  1. 7.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  4. 7.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026)
  5. 7.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032)
  6. 7.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Analysis
  2. 9.1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Mode & Process
  6. 9.2 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
  9. 9.2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst